AIC expands ability to serve patients

By HME News Staff
Updated 8:48 AM CST, Mon January 20, 2025
DALLAS – AIC, a division of AIS Healthcare, now offers ALYGLO, manufactured by GC Biopharma, for the treatment of adult patients with primary humoral immunodeficiency (PI). This new immunoglobulin (Ig) therapeutic option will expand the company’s ability to better serve PI patients in their home or an infusion suite setting. “We are excited to add ALGYLO to our expansive list of Ig infusion therapies,” said Jud Hall, president of AIC. “AIC is proud to partner with GC Biopharma to offer this extra-purified IVIg replacement therapy as another treatment option to patients nationwide,” added Stan Singley, vice president of trade & procurement. Approved by the U.S. Food and Drug Administration in 2023, ALGYLO is now available at all AIC locations (Valdosta, Ga.; Birmingham, Ala.; Panama City, Fla.; Cockeysville, Md; and Dallas). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID). The company says AIC patients receive a high level of care, including 24/7 access to clinical and support staff and a dedicated team of professionals comprised of clinical pharmacists, home infusion nurses, RN clinical review specialists and patient access specialists. AIS Healthcare is dually accredited by URAC and the Accreditation Commission for Health Care (ACHC).
Comments